Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 20/20 | 0.56 |
| ▸ | ITGA4 | P13612 | 20/20 | 0.56 |
| ▸ | ITGB7 | P26010 | 12/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5162116 | 0.89 | ITGB1 (0.69) | ITGB1ITGA4ITGB7 | |
| SCHEMBL8245071 | 0.88 | ITGA4 (0.43) | ITGB1ITGA4ITGB7 | |
| SCHEMBL2108815 | 0.88 | ITGA4 (0.41) | ITGB1ITGA4ITGB7 | |
| SCHEMBL2771475 | 0.88 | ITGA4 (0.41) | ITGB1ITGA4ITGB7 | |
| SCHEMBL2059097 | 0.88 | ITGB1 (0.47) | ITGB1ITGA4 | |
| SCHEMBL2608694 | 0.88 | ITGB1 (0.60) | ITGB1ITGA4ITGB7 | |
| SCHEMBL2847610 | 0.88 | ITGB1 (0.60) | ITGB1ITGA4ITGB7 | |
| SCHEMBL4201731 | 0.88 | ITGB1 (0.58) | ITGB1ITGA4ITGB7 | |
| SCHEMBL12193526 | 0.88 | ITGB1 (0.41) | ITGB1ITGA4ITGB7 | |
| SCHEMBL8251348 | 0.88 | ITGA4 (0.46) | ITGB1ITGA4ITGB7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8269009-B2 | Methods and compositions for treating liquid tumors | ELAN PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| EP-2231185-A1 | METHODS AND COMPOSITIONS FOR TREATING LIQUID TUMORS | Elan Pharmaceuticals Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| EP-1507533-B1 | HETEROARYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA-4 INTEGRINS | ELAN PHARM INC (US) | 2010-04-14 | — | — | EP | disclosed |
| US-20090312353-A1 | Methods and compositions for treating liquid tumors | ELAN PHARMACEUTICALS, INC. | 2009-12-17 | — | — | US | disclosed |
| US-7605166-B2 | Synergistic mixture of methotrexate and integrin antigen or antibody | ELAN PHARMACEUTICALS INC. (US) | 2009-10-20 | — | — | US | disclosed |
| EP-1635822-A4 | METHODS AND COMPOSITIONS FOR TREATING RHEUMATOID ARTHRITIS | ELAN PHARM INC (US) | 2009-06-24 | — | — | EP | disclosed |
| WO-2009075806-A1 | METHODS AND COMPOSITIONS FOR TREATING LIQUID TUMORS | ELAN PHARMACEUTICALS, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| US-7335663-B2 | Heteroaryl compounds which inhibit leukocyte adhesion mediated by α4 integrins | ELAN PHARMACEUTICALS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| EP-1635871-A4 | METHODS AND COMPOSITIONS FOR TREATING RHEUMATOID ARTHRITIS | ELAN PHARM INC (US) | 2007-07-18 | — | — | EP | disclosed |
| EP-1507533-A4 | HETEROARYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA-4 INTEGRINS | ELAN PHARM INC (US) | 2007-05-23 | — | — | EP | disclosed |
| EP-1635871-A2 | METHODS AND COMPOSITIONS FOR TREATING RHEUMATOID ARTHRITIS | Elan Pharmaceuticals, Inc. (US) | 2006-03-22 | — | — | EP | disclosed |
| US-7008949-B2 | Heterocyclic compounds which inhibit leukocyte adhesion mediated by α4 integrins | ELAN PHARMACEUTICALS, INC. (US) | 2006-03-07 | — | — | US | disclosed |
| US-20050130999-A1 | Heteroaryl compounds which inhibit leukocyte adhesion mediated by alpha-4 integrins | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2005-06-16 | — | — | US | disclosed |
| US-20050074451-A1 | Methods and compositions for treating rheumatoid arthritis | ELAN PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| US-20050065192-A1 | Methods and compositions for treating rheumatoid arthritis | ELAN PHARMACEUTICALS, INC. (US) | 2005-03-24 | — | — | US | disclosed |
| EP-1507533-A2 | HETEROARYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA-4 INTEGRINS | Elan Pharmaceuticals, Inc. (US) | 2005-02-23 | — | — | EP | disclosed |
| WO-2005000244-A2 | METHODS AND COMPOSITIONS FOR TREATING RHEUMATOID ARTHRITIS | ELAN PHARMACEUTICALS, INC. (US) | 2005-01-06 | — | — | WO | disclosed |
| WO-2005000246-A2 | METHODS AND COMPOSITIONS FOR TREATING RHEUMATOID ARTHRITIS | ELAN PHARMACEUTICALS, INC. (US) | 2005-01-06 | — | — | WO | disclosed |
| US-20040142954-A1 | Heteroaryl compounds which inhibit leukocyte adhesion mediated by alpha4 integrins | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2004-07-22 | — | — | US | disclosed |
| WO-2003099231-A2 | HETEROARYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA-4 INTEGRINS | ELAN PHARMACEUTICALS, INC. (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130999-A1 | Heteroaryl compounds which inhibit leukocyte adhesion mediated by alpha-4 integrins | ITGB4, VCAM1, ITGA4 | ITGB1 8/4885ITGA4 3/4885ITGB7 32/4885 |
| US-20090312353-A1 | Methods and compositions for treating liquid tumors | ITGB4, ITGA4, ITGB3 | ITGB1 4/4885ITGA4 2/4885ITGB7 13/4885 |
| US-20050065192-A1 | Methods and compositions for treating rheumatoid arthritis | VCAM1, ICAM1, ITGA4 | ITGB1 8/4885ITGA4 3/4885ITGB7 38/4885 |
| US-20040142954-A1 | Heteroaryl compounds which inhibit leukocyte adhesion mediated by alpha4 integrins | VCAM1, ITGB4, ITGA4 | ITGB1 10/4885ITGA4 3/4885ITGB7 30/4885 |
| US-20050074451-A1 | Methods and compositions for treating rheumatoid arthritis | VCAM1, ICAM1, ITGA4 | ITGB1 8/4885ITGA4 3/4885ITGB7 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.